S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NYSEAMERICAN:MTNB

Matinas BioPharma News Headlines

$1.14
+0.03 (+2.70 %)
(As of 10/18/2021 04:27 PM ET)
Add
Compare
Today's Range
$1.11
$1.15
50-Day Range N/A
52-Week Range
$0.67
$2.22
Volume774,184 shs
Average Volume2.76 million shs
Market Capitalization$244.80 million
P/E RatioN/A
Dividend YieldN/A
Beta2.37

Media Mentions By Week

Matinas BioPharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MTNB
News Sentiment

-0.24

0.35

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MTNB Articles
This Week

0

1

MTNB Articles
Average Week

Get Matinas BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

Matinas BioPharma (NYSEAMERICAN MTNB) News Headlines Today

SourceHeadline
finance.yahoo.com logoMatinas Biopharma Holdings, Inc. (MTNB) Upgraded to Buy: Here's What You Should Know
finance.yahoo.com - October 5 at 5:42 PM
markets.businessinsider.com logoPre-market Movers: GOVX, ITRM, GREE, RGS, MTNB…
markets.businessinsider.com - September 29 at 10:48 AM
finance.yahoo.com logoMatinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
finance.yahoo.com - September 20 at 7:05 AM
msn.com logoWhy Matinas BioPharma's Stock Is Trading Higher Today
msn.com - September 14 at 5:01 PM
finance.yahoo.com logoMatinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference
finance.yahoo.com - September 14 at 7:37 AM
finance.yahoo.com logoMatinas BioPharma Stock Jumps After Meningitis Candidate Data
finance.yahoo.com - September 13 at 4:35 PM
nasdaq.com logoMatinas BioPharma Reports Positive Data From First Half Of EnACT Study - Quick Facts
nasdaq.com - September 13 at 7:54 AM
finance.yahoo.com logoMatinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
finance.yahoo.com - September 13 at 7:54 AM
finance.yahoo.com logoMatinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections
finance.yahoo.com - August 16 at 7:15 AM
nasdaq.com logoMatinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
nasdaq.com - August 10 at 9:13 AM
finance.yahoo.com logoMatinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
finance.yahoo.com - August 10 at 7:27 AM
benzinga.com logoMatinas BioPharma Hldgs Earnings Preview
benzinga.com - August 9 at 1:29 PM
finance.yahoo.com logoMatinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
finance.yahoo.com - August 3 at 7:39 AM
finance.yahoo.com logoMatinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021
finance.yahoo.com - July 27 at 8:12 AM
benzinga.com logoMatinas BioPharma Hldgs: Return On Capital Employed Insights
benzinga.com - June 23 at 1:16 PM
benzinga.com logoReturn On Capital Employed Overview: Matinas BioPharma Hldgs
benzinga.com - June 7 at 11:24 AM
finance.yahoo.com logoMatinas BioPharma to Hold Virtual R&D Day on June 17, 2021
finance.yahoo.com - May 20 at 8:15 AM
finance.yahoo.com logoMatinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 10 at 8:37 AM
finance.yahoo.com logoMatinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
finance.yahoo.com - May 10 at 8:06 AM
benzinga.com logoMatinas BioPharma Hldgs's Earnings: A Preview
benzinga.com - May 7 at 11:08 AM
finance.yahoo.com logoMatinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
finance.yahoo.com - April 28 at 7:54 AM
feeds.benzinga.com logoMatinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021
feeds.benzinga.com - April 27 at 7:40 AM
finance.yahoo.com logoMatinas BioPharma to Present at the Needham Healthcare Conference
finance.yahoo.com - April 8 at 7:51 AM
finance.yahoo.com logoWe're Not Very Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Rate
finance.yahoo.com - April 1 at 12:33 PM
seekingalpha.com logoMatinas Biopharma EPS in-line, misses on revenue
seekingalpha.com - March 30 at 5:39 PM
seekingalpha.com logoMatinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 30 at 1:51 PM
finance.yahoo.com logoMatinas Posts Quarterly Loss In-Line With Expectations
finance.yahoo.com - March 29 at 10:03 AM
finance.yahoo.com logoMatinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
finance.yahoo.com - March 29 at 7:48 AM
benzinga.com logoMatinas BioPharma Earnings Outlook
benzinga.com - March 26 at 12:48 PM
markets.businessinsider.com logoMatinas BioPharma Holdings Inc hosts conference call for investors
markets.businessinsider.com - March 17 at 2:48 PM
bloomberg.com logoMatinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on
bloomberg.com - March 17 at 8:27 AM
finance.yahoo.com logoMatinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021
finance.yahoo.com - March 15 at 7:32 AM
finance.yahoo.com logoMatinas BioPharma to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - March 1 at 7:38 AM
finance.yahoo.com logoMatinas BioPharma to Present at the ICR Conference 2021
finance.yahoo.com - January 6 at 8:30 AM
marketwatch.com logoMatinas BioPharma Announces FDA Conditional Acceptance of LYPDISO(TM) as the Brand Name for MAT9001
marketwatch.com - January 5 at 11:59 PM
finance.yahoo.com logoWhy Matinas BioPharma Holdings Shot Almost 28% Higher Today
finance.yahoo.com - January 4 at 7:47 PM
finance.yahoo.com logoMatinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001
finance.yahoo.com - January 4 at 8:23 AM
marketwatch.com logoThinking about buying stock in Gevo, Ocugen, Riot Blockchain, Matinas BioPharma, or Blink Charging?
marketwatch.com - December 30 at 1:42 PM
finance.yahoo.com logoThese 2 Penny Stocks Are Poised to Go Boom, Say Analysts
finance.yahoo.com - December 29 at 1:54 PM
finance.yahoo.com logoMatinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders
finance.yahoo.com - December 7 at 7:17 AM
finance.yahoo.com logoMatinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
finance.yahoo.com - December 7 at 7:17 AM
finance.yahoo.com logoMatinas Biopharma Holdings, Inc. (MTNB) Fell Out Of Favor With Hedge Funds
finance.yahoo.com - December 2 at 9:45 PM
finance.yahoo.com logoMatinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
finance.yahoo.com - December 1 at 7:53 AM
finance.yahoo.com logoMatinas BioPharma (MTNB) Looks Good: Stock Adds 8.6% in Session
finance.yahoo.com - November 27 at 10:04 AM
proactiveinvestors.com logoMatinas BioPharma awarded $3.75M from Cystic Fibrosis Foundation to advance pre-clinical development of MAT2501
proactiveinvestors.com - November 20 at 1:13 PM
businesswire.com logoCF Foundation Awards up to $3.75M to Matinas BioPharma to Develop Oral Version of Antibiotic for NTM Infections
businesswire.com - November 20 at 10:59 AM
seekingalpha.com logoMatinas Bio secures $3.75M grant to support development of MAT2501
seekingalpha.com - November 20 at 8:12 AM
finance.yahoo.com logoMatinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients
finance.yahoo.com - November 20 at 8:12 AM
finance.yahoo.com logoMatinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
finance.yahoo.com - November 19 at 6:01 PM
finance.yahoo.com logoMatinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
finance.yahoo.com - November 10 at 7:33 AM
Get Matinas BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.